Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD
Status:
Completed
Trial end date:
2017-02-06
Target enrollment:
Participant gender:
Summary
The study was designed to investigate the efficacy and safety of different doses CHF5259 a
long acting muscarinic antagonist in patients with moderate to severe COPD.